Typhoid conjugate vaccine implementation in India: A review of supportive evidence.

Autor:	Mogasale VV; Department of Infectious Disease Epidemiology and Dynamics, London School of Hygiene & Tropical Medicine, London, UK.; School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan., Sinha A; Indian Institute of Public Health-Gandhinagar, India., John J; Department of Community Health, Christian Medical College, Vellore, India., Hasan Farooqui H; College of Medicine, Qatar University, Doha, Qatar., Ray A; Department of Infectious Disease & Vaccine Delivery, Bill and Melinda Gates Foundation, New Delhi, India., Chantler T; Department of Global Health and Development, London School of Hygiene & Tropical Medicine, London, UK., Mogasale V; Graduate School of Public Health, Yonsei University, Seoul, Republic of Korea (Current affiliation: Health Financing and Economics Department, World Health Organisation, Geneva, Switzerland)., Gopal Dhoubhadel B; School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan.; Department of Clinical Medicine and Research, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan., John Edmunds W; Department of Infectious Disease Epidemiology and Dynamics, London School of Hygiene & Tropical Medicine, London, UK.; School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan.; Department of Infectious Disease Epidemiology and Dynamics, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan., Clark A; Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK., Abbas K; Department of Infectious Disease Epidemiology and Dynamics, London School of Hygiene & Tropical Medicine, London, UK.; School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan.; Department of Infectious Disease Epidemiology and Dynamics, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.; Public Health Foundation of India, New Delhi, India.
Jazyk:	angličtina
Zdroj:	Vaccine: X [Vaccine X] 2024 Oct 01; Vol. 21, pp. 100568. Date of Electronic Publication: 2024 Oct 01 (Print Publication: 2024).
DOI:	10.1016/j.jvacx.2024.100568
Abstrakt:	Background: Typhoid conjugate vaccines are available in the private market in India and are also recommended by the National Technical Advisory Group on Immunisation (NTAGI) for inclusion in India's Universal Immunisation Programme in 2022 to control and prevent typhoid fever. Our study aims to synthesise the supportive evidence for typhoid conjugate vaccine implementation in the routine immunisation programme of India. Methods: We conducted a literature review to identify supportive evidence for typhoid conjugate vaccine implementation in India based on the key criteria of the World Health Organisation's Evidence-to-Recommendation framework for National Immunisation Technical Advisory Groups. Results: We synthesised evidence on typhoid disease burden, benefits and harms of typhoid conjugate vaccine, cost-effectiveness analysis, and implementation feasibility. However, the in-country evidence on budget impact analysis, vaccine demand and supply forecast, equity analysis, target population values and preferences, immunisation service providers' acceptability, co-administration safety, and antimicrobial resistance tracking were limited. Conclusion: Based on the literature review, we identified evidence gaps. We recommend identifying research priorities for supporting typhoid conjugate vaccine implementation decision-making in India by combining evidence gaps with the perceived importance of the same evidence criteria and factors among immunisation stakeholders. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2024 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu